In this Editorial Article, Dr. Erik Tillman, Principal Scientist at Akero Therapeutics, describes his company’s quest to find an effective treatment for non-alcoholic steatohepatitis and how the functional iLite assay-ready cells they use deliver robust, reproducible, and convenient ready-to-use cells that accelerate their research and support project goals.
The article also deals with the challenges that a virtual company faces and how forging relationships with trusted contract research organizations, like Svar Life Science, can ease and speed up the development process.